Abrdn Life Sciences Investors (NYSE:HQL) Sees Significant Decline in Short Interest

Abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 33,800 shares, a drop of 54.4% from the November 15th total of 74,100 shares. Based on an average daily trading volume, of 75,400 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Trading of Abrdn Life Sciences Investors

Institutional investors and hedge funds have recently modified their holdings of the company. Future Financial Wealth Managment LLC bought a new position in Abrdn Life Sciences Investors in the 3rd quarter worth $30,000. Ashton Thomas Securities LLC purchased a new position in shares of Abrdn Life Sciences Investors in the third quarter valued at about $148,000. Sanctuary Advisors LLC bought a new position in shares of Abrdn Life Sciences Investors in the second quarter worth about $154,000. Kapstone Financial Advisors LLC purchased a new stake in shares of Abrdn Life Sciences Investors during the third quarter worth about $177,000. Finally, Stephens Inc. AR raised its stake in Abrdn Life Sciences Investors by 7.6% during the 3rd quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after purchasing an additional 896 shares during the period. 32.21% of the stock is currently owned by institutional investors.

Abrdn Life Sciences Investors Trading Down 1.0 %

Shares of NYSE:HQL traded down $0.14 during mid-day trading on Friday, reaching $13.84. 73,123 shares of the company traded hands, compared to its average volume of 92,054. The company’s 50 day moving average price is $14.58 and its 200-day moving average price is $14.71. Abrdn Life Sciences Investors has a 52 week low of $12.76 and a 52 week high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Thursday, November 21st will be given a $0.50 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. This represents a $2.00 dividend on an annualized basis and a dividend yield of 14.45%. The ex-dividend date is Thursday, November 21st.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.